Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
CeloNova BioSciences, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients older than age 18 with ischemic symptoms (stable or unstable angina or NSTEMI without thrombosis of the target lesion on coronary angiography) or evidence of myocardial ischemia in the presence of ≥ 50% de novo stenosis located in native coronary vessels (max. 2 lesions in one or 2 separate vessels).
Patient receiving or with an indication for new treatment with long-term oral anticoagulation with a coumadin derivatives or non-vitamin K oral anticoagulants.
Written, informed consent
You may not be if
Cardiogenic shock
Target lesion located in left main trunk
Bifurcation interventions with a planned 2-stent strategy
Vessel size too small for implantation of a 2.5 mm stent by visual estimation
Patient requiring staging PCI procedure within 6 months after the index procedure
Patients requiring DAPT for more than 2 weeks after the index procedure
Contraindications or allergy to cobalt, chromium, platinum, polyzene-F, everolimus, zotarolimus or the inability to take triple therapy for at least 6 months
Relevant hematologic deviations: platelet count \<100x10\^9 cells/L or \>600x10\^9 cells/L
Active bleeding; bleeding diathesis; recent trauma or major surgery in the last month; history of intracranial bleeding or structural abnormalities; suspected aortic dissection
Malignancies or other co-morbid conditions with life expectancy less than 12 months or that may result in protocol non-compliance
Pregnancy, present (positive pregnancy test), suspected or planned, breast feeding
Known allergy or intolerance to the study medications: ASA, clopidogrel, coumadin and its derivatives
Patient's inability to fully cooperate with the study protocol
Clareo Health | Randomized Trial of COBRA PzF Stenting to Reduce Duration of Triple Therapy
